Clinical Trials
6
Active:0
Completed:6
Trial Phases
4 Phases
Phase 1:1
Phase 2:2
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)β’ Click on a phase to view related trials
Phase 2
2 (33.3%)Phase 3
2 (33.3%)Phase 1
1 (16.7%)Phase 4
1 (16.7%)A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
- First Posted Date
- 2010-12-31
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT01268839
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
Phase 2
Completed
- Conditions
- Human Immunodeficiency Virus (HIV)
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT01199939
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
Phase 4
Completed
- Conditions
- HIV
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT00757783
A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 23
- Registration Number
- NCT00534352
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Tibotec, Inc
- Target Recruit Count
- 10
- Registration Number
- NCT00460746
- Prev
- 1
- 2
- Next
News
No news found